Background: Many survivors of cardiovascular arrest remain in a postanoxic coma. The neurologist's task is to provide the most accurate assessment of the patient's neurologic prognosis through a multimodal approach of clinical and technical tests. The aim of this study is to analyze differences and developments in the concept of neurological prognosis assessment and in-hospital outcome of patients over a five year-period.
Methods: This retrospective observational study included 227 patients with postanoxic coma treated in the medical intensive care unit of the University Hospital, Mannheim from January 2016 to May 2021. We retrospectively analyzed patient characteristics, post-cardiac arrest care, and the use of clinical and technical tests for neurological prognosis assessment and patient outcome.
Results: Over the observation period, 215 patients received a completed neurological prognosis assessment. Regarding the multimodal prognostic assessment, patients with poor prognosis (54%) received significantly fewer diagnostic modalities than patients with very likely poor (20.5%), indeterminate (24.2%), or good prognosis (1.4%; = 0.001). The update of the DGN guidelines in 2017 had no effect on the number of performed prognostic parameters per patient. The finding of bilaterally absent pupillary light reflexes or severe anoxic injury on CT contributed most to a poor prognosis category (OR 8.38, 95%CI 4.01-7.51 and 12.93, 95%CI 5.55-30.13, respectively), whereas a malignant EEG pattern and NSE > 90 µg/L at 72 h resulted in the lowest OR (5.11, 95%CI 2.32-11.25, and 5.89, 95%CI 3.14-11.06, respectively) for a poor prognosis category. Assessment of baseline NSE significantly increased over the years (OR 1.76, 95%CI 1.4-2.22, < 0.001), and assessment of follow-up NSE at 72 h trended to increase (OR 1.19, 95%CI 0.99-1.43, = 0.06). In-hospital mortality was high (82.8%), remained unchanged over the observation period, and corresponded to the number of patients in whom life-sustaining measures were discontinued.
Conclusions: Among comatose survivors of cardiac arrest, the prognosis remains poor. Prognostication of a poor outcome led nearly exclusively to withdrawal of care. Prognostic modalities varied considerably with regard to their contribution to a poor prognosis category. Increasing enforcement of a standardized prognosis assessment and standardized evaluation of diagnostic modalities are needed to avoid false-positive prognostication of poor outcomes.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10218778 | PMC |
http://dx.doi.org/10.3390/jcm12103357 | DOI Listing |
Alzheimers Dement
December 2024
Weill Cornell Medicine, New York City, NY, USA.
Background: Early detection of Alzheimer's disease (AD) can improve prognosis, given new anti-amyloid therapies. Both positron emission tomography (PET) and magnetic resonance (MR) imaging biomarkers are currently used (1). 48F-Fluorodeoxyglucose-PET (FDG-PET) can detect neurodegeneration-related hypometabolism but is costly and not easily accessible (2).
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Post Graduate Institute of Medical Education and Research, Chandigarh, Chandigarh, India.
Background-: An estimated 8.8 million Indians older than 60 years have dementia. The increase in number of people living with dementia is causing difficultly to meet the need for care and support, particularly people with early-stage dementia.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
First Institute of All Medicines, Milford, DE, USA.
Background: Alzheimer's disease (AD) poses a significant global health challenge, which demands innovative therapeutic approaches. The strong biophoton field generated by breakthrough medical devices has preliminarily shown a high rate of success in improving cognition and life quality of the patients with AD.
Method: This was a randomized triple blinded placebo controlled clinical study to verify if biophotons can improve cognition of AD.
Anticancer Agents Med Chem
January 2025
Department of Dermatology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221002, Jiangsu, China.
Introduction: Immunotherapy targeting PD-1/PD-L1 shows significant benefits in lung cancer. Cutaneous immune-related adverse events (irAEs) are frequent, early-developing side effects of ICIs, and their potential role as prognostic markers in non-small cell lung cancer (NSCLC) therapy requires further exploration.
Methods: Data of patients with NSCLC treated with camrelizumab Combined with chemotherapy were collected at Xuzhou Medical University from 2019 to 2023.
Comb Chem High Throughput Screen
January 2025
Department of Gynecology, Affiliated Xingtai People Hospital of Hebei Medical University, China.
Introduction: Ovarian Cancer (OC) was known for its high mortality rate among gynecological malignancies, often resulting in a poor prognosis. This study sought to identify prognostic necroptosis-related long non-coding RNAs (lncRNAs) (NRlncRNAs) with prognostic potential and to construct a reliable risk prediction model for OC patients.
Method: The transcriptome and clinic data were sourced from TCGA and GTEx databases.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!